Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC) (LAPACT)
Nab-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT).
Sponsor: Celgene
Listed as NCT02301143, this PHASE2 trial focuses on Pancreatic Neoplasms and remains completed. Sponsored by Celgene, it has been updated 12 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Feb 2019 — Apr 2019 [monthly]
Completed PHASE2
-
Aug 2018 — Feb 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Angers, France , Ann Arbor, United States , Atlanta, United States , Barcelona, Spain , Benevento, Italy , Besançon, France , Boston, United States , Buffalo, United States , Calgary, Canada and 30 more locations